We are broadly interested in the biology of mycobacteria, which include the major human pathogen M. tuberculosis, the nonpathogenic model organism M. smegmatis, and the cancer biotherapeutic agent BCG.
Michael S. Glickman, MD
Professor
Research Focus
Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including regulated intramembrane proteolysis (the Rip1 pathway); double-strand-break repair and associated DNA damage responses; and cell envelope biosynthesis.Education
MD, Columbia University College of Physicians and Surgeons- Office Phone: 646-888-2368
- Office Fax: 646-422-0502
- Lab Phone: 646-888-2360
- Lab Fax: 646-422-0502
Lab Members
Michael Glickman
Member
John Buglino
Research Scholar
Allison Fay
Research Scholar
Gil Redelman-Sidi
Assistant member L1
Oyindamola Adefisayo
Graduate Student
Anthony Antonelli
Graduate Student
Jamie Bean
TBRU Data Coordinator
Anna Binyamin
Senior Research Technician
Olivier Levy
Postdoctoral Fellow
Charles Vorkas
ID fellow
Matthew Wipperman
Postdoctoral Fellow
Publications
- Wipperman MF, Heaton BE, Nautiyal A, Adefisayo O, Evans H, Gupta R, van Ditmarsch D, Soni R, Hendrickson R, Johnson J, Krogan N, Glickman MS. Mycobacterial Mutagenesis and Drug Resistance Are Controlled by Phosphorylation- and Cardiolipin-Mediated Inhibition of the RecA Coprotease. Mol Cell. 2018 Aug 22. pii: S1097-2765(18)30606-3. doi: 10.1016/j.molcel.2018.07.037. [Epub ahead of print] PubMed
- Redelman-Sidi, G., Iyer, G., Solit, D., and Glickman, M.S. Oncogenic activation of Pak1 dependent Macropinocytosis pathway determines BCG entry into bladder cancer cells. Cancer Res. 2013 Feb 1;73(3):1156-67.
